| Molecular biology in breast cancer: intrinsic subtypes and signaling pathways P Eroles, A Bosch, JA Pérez-Fidalgo, A Lluch Cancer treatment reviews 38 (6), 698-707, 2012 | 971 | 2012 |
| Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research A Bosch, P Eroles, R Zaragoza, JR Viña, A Lluch Cancer treatment reviews 36 (3), 206-215, 2010 | 445 | 2010 |
| PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor–positive breast cancer A Bosch, Z Li, A Bergamaschi, H Ellis, E Toska, A Prat, JJ Tao, DE Spratt, ... Science translational medicine 7 (283), 283ra51-283ra51, 2015 | 361 | 2015 |
| mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer M Elkabets, S Vora, D Juric, N Morse, M Mino-Kenudson, T Muranen, ... Science translational medicine 5 (196), 196ra99-196ra99, 2013 | 320 | 2013 |
| Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study J Staaf, D Glodzik, A Bosch, J Vallon-Christersson, C Reuterswärd, ... Nature medicine 25 (10), 1526-1533, 2019 | 260 | 2019 |
| Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients I Chirivella, B Bermejo, A Insa, A Pérez-Fidalgo, A Magro, S Rosello, ... Breast cancer research and treatment 114, 479-484, 2009 | 225 | 2009 |
| Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer J Cortes, J Rodriguez, JM Aramendia, E Salgado, A Gurpide, ... Oncology 64 (1), 28-35, 2002 | 189 | 2002 |
| Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer JJ Tao, P Castel, N Radosevic-Robin, M Elkabets, N Auricchio, N Aceto, ... Science signaling 7 (318), ra29-ra29, 2014 | 172 | 2014 |
| Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy C Saura, J Bendell, G Jerusalem, S Su, Q Ru, S De Buck, D Mills, ... Clinical Cancer Research 20 (7), 1935-1945, 2014 | 148 | 2014 |
| Strategies to design clinical studies to identify predictive biomarkers in cancer research JL Perez-Gracia, MF Sanmamed, A Bosch, A Patiño-Garcia, KA Schalper, ... Cancer Treatment Reviews 53, 79-97, 2017 | 109 | 2017 |
| Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer J Climent, J Perez-Losada, DA Quigley, IJ Kim, R Delrosario, KY Jen, ... Journal of Clinical Oncology 28 (23), 3770-3778, 2010 | 87 | 2010 |
| High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer S Kimbung, B Lettiero, M Feldt, A Bosch, S Borgquist Oncotarget 7 (37), 59640, 2016 | 85 | 2016 |
| Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution … P Martin-Martorell, S Rosello, E Rodriguez-Braun, I Chirivella, A Bosch, ... British journal of cancer 99 (3), 455-458, 2008 | 79 | 2008 |
| The X-linked DDX3X RNA helicase dictates translation reprogramming and metastasis in melanoma B Phung, M Cieśla, A Sanna, N Guzzi, G Beneventi, PCT Ngoc, M Lauss, ... Cell reports 27 (12), 3573-3586. e7, 2019 | 75 | 2019 |
| Removal of primary tumor improves survival in metastatic breast cancer. Does timing of surgery influence outcomes? JA Pérez-Fidalgo, P Pimentel, A Caballero, B Bermejo, JA Barrera, ... The breast 20 (6), 548-554, 2011 | 74 | 2011 |
| MicroRNA profile in very young women with breast cancer M Peña-Chilet, MT Martínez, JA Pérez-Fidalgo, L Peiró-Chova, SS Oltra, ... BMC cancer 14, 1-14, 2014 | 73 | 2014 |
| Nitration of cathepsin D enhances its proteolytic activity during mammary gland remodelling after lactation R Zaragozá, L Torres, C García, P Eroles, F Corrales, A Bosch, A Lluch, ... Biochemical Journal 419 (2), 279-288, 2009 | 34 | 2009 |
| Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: results from the Swedish PREDIX HER2 trial identifying … JCS Bergh, A Andersson, J Bjohle, A Bosch, L Carlsson, AC Dreifaldt, ... Journal of Clinical Oncology 37 (15_suppl), 501-501, 2019 | 28 | 2019 |
| Mechanisms of resistance to hormonal treatment in breast cancer P Eroles, A Bosch, B Bermejo, A Lluch Clinical and Translational Oncology 12, 246-252, 2010 | 22 | 2010 |
| Nitric oxide triggers mammary gland involution after weaning: remodelling is delayed but not impaired in mice lacking inducible nitric oxide synthase R Zaragozá, A Bosch, C García, J Sandoval, E Serna, L Torres, ... Biochemical Journal 428 (3), 451-462, 2010 | 18 | 2010 |
J. Alejandro Pérez FidalgoHospital Clinico Universitario Valencia. Research Institute INCLIVA. University ValenciaVerified email at uv.es
